Australia's National Health and Medical Research Council (NHMRC) has issued interim guidance recommending puberty blockers as a potential treatment option for transgender and gender-diverse children under 18. This recommendation comes as the country grapples with differing approaches to gender-affirming care, with some Australian states implementing restrictions while other nations, like the UK and numerous US states, have moved to ban or limit access to these medications.
The interim guidance, now open for public consultation, suggests that puberty blockers can be considered for individuals under 18 experiencing "gender incongruence" – a mismatch between their sex assigned at birth and their gender identity. Eligibility requires the young person to have started puberty, undergo a suitability assessment, and for the treatment decision to be made collaboratively by the individual, their parents or carers, and clinicians.
Federal Health Minister Mark Butler stated that the NHMRC's advice supports the use of puberty blockers under strict safeguards and in specific circumstances. He emphasized the necessity of a shared decision-making process involving the young person, parents, and clinicians, alongside thorough health assessments, multidisciplinary input, and ongoing patient monitoring.
This development follows the Australian government's commissioning of national guidelines for the care of trans and gender-diverse youth in 2025. The issue has gained prominence internationally, influenced partly by the UK's independent Cass Review, which found limited and low-quality evidence supporting the use of puberty blockers and cross-sex hormones for children and adolescents with gender distress. The review called for a more cautious, evidence-based approach.
In contrast to Australia's interim recommendation, the United States remains divided. While puberty blockers are legal for non-transgender medical conditions nationwide, 24 states have implemented restrictions or bans on their use for transgender minors. This has been shaped by legislative changes and court decisions affirming states' rights to regulate gender-affirming treatments for children.
The NHMRC classified its recommendation as "conditional," acknowledging the ongoing limited evidence regarding the benefits and risks of puberty blockers. All treatment decisions are to be made on an individual basis.
The new guidance could place pressure on Queensland and the Northern Territory, which have already restricted access to puberty blockers and gender-affirming hormones within their public health systems. Queensland's government has a ministerial direction preventing public hospitals from initiating new treatments for under-18s for gender dysphoria, a ban extended until 2031. The Northern Territory has also halted new publicly funded prescriptions for minors, though private prescriptions remain possible, and mental health support is available.
Minister Butler indicated that while the federal government would not intervene in existing state laws, he acknowledged the historical respect state governments have shown for the NHMRC's advice. Nationally, puberty blockers remain legal and can be prescribed by Australian clinicians, though they are typically provided off-label and are not subsidized through the Pharmaceutical Benefits Scheme for gender-related treatments.